These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29518282)

  • 61. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
    Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
    Villemagne VL; Pike KE; Chételat G; Ellis KA; Mulligan RS; Bourgeat P; Ackermann U; Jones G; Szoeke C; Salvado O; Martins R; O'Keefe G; Mathis CA; Klunk WE; Ames D; Masters CL; Rowe CC
    Ann Neurol; 2011 Jan; 69(1):181-92. PubMed ID: 21280088
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [
    Wagatsuma K; Miwa K; Kamitaka Y; Koike E; Yamao T; Yoshii T; Kobayashi R; Nezu S; Sugamata Y; Miyaji N; Imabayashi E; Ishibashi K; Toyohara J; Ishii K
    Med Phys; 2022 May; 49(5):2995-3005. PubMed ID: 35246870
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
    Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.
    Rostomian AH; Madison C; Rabinovici GD; Jagust WJ
    J Nucl Med; 2011 Feb; 52(2):173-9. PubMed ID: 21233181
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Myoinositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury.
    Kierans AS; Kirov II; Gonen O; Haemer G; Nisenbaum E; Babb JS; Grossman RI; Lui YW
    Neurology; 2014 Feb; 82(6):521-8. PubMed ID: 24401686
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
    Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Longitudinal head-to-head comparison of
    Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
    Wong DF; Rosenberg PB; Zhou Y; Kumar A; Raymont V; Ravert HT; Dannals RF; Nandi A; Brasić JR; Ye W; Hilton J; Lyketsos C; Kung HF; Joshi AD; Skovronsky DM; Pontecorvo MJ
    J Nucl Med; 2010 Jun; 51(6):913-20. PubMed ID: 20501908
    [TBL] [Abstract][Full Text] [Related]  

  • 71. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome.
    Parmera JB; Coutinho AM; Aranha MR; Studart-Neto A; de Godoi Carneiro C; de Almeida IJ; Fontoura Solla DJ; Ono CR; Barbosa ER; Nitrini R; Buchpiguel CA; Brucki SMD
    Mov Disord; 2021 Mar; 36(3):651-661. PubMed ID: 33206389
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.
    Knopman DS; Jack CR; Lundt ES; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Machulda MM; Roberts RO; Boeve BF; Jones DT; Petersen RC
    JAMA Neurol; 2015 Dec; 72(12):1475-83. PubMed ID: 26437123
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease.
    Yan L; Liu CY; Wong KP; Huang SC; Mack WJ; Jann K; Coppola G; Ringman JM; Wang DJJ
    Neuroimage Clin; 2018; 17():751-760. PubMed ID: 29527482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.
    Mosconi L; Rinne JO; Tsui WH; Murray J; Li Y; Glodzik L; McHugh P; Williams S; Cummings M; Pirraglia E; Goldsmith SJ; Vallabhajosula S; Scheinin N; Viljanen T; Någren K; de Leon MJ
    Neurobiol Aging; 2013 Jan; 34(1):22-34. PubMed ID: 22503001
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
    Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
    Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.